ID   CANT1_HUMAN             Reviewed;         401 AA.
AC   Q8WVQ1; B4DJ54; Q7Z2J7; Q8NG05; Q8NHP0; Q9BSD5;
DT   10-MAY-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 1.
DT   28-JUN-2023, entry version 172.
DE   RecName: Full=Soluble calcium-activated nucleotidase 1;
DE            Short=SCAN-1;
DE            EC=3.6.1.6 {ECO:0000269|PubMed:12234496, ECO:0000269|PubMed:15006348, ECO:0000269|PubMed:15248776, ECO:0000269|PubMed:16835225};
DE   AltName: Full=Apyrase homolog;
DE   AltName: Full=Putative MAPK-activating protein PM09;
DE   AltName: Full=Putative NF-kappa-B-activating protein 107;
GN   Name=CANT1; Synonyms=SHAPY;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   COFACTOR, SUBUNIT, SUBCELLULAR LOCATION, GLYCOSYLATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Mammary tumor;
RX   PubMed=12234496; DOI=10.1016/s0003-9861(02)00420-4;
RA   Smith T., Hicks-Berger C., Kim S., Kirley T.;
RT   "Cloning, expression, and characterization of a soluble calcium-activated
RT   nucleotidase, a human enzyme belonging to a new family of extracellular
RT   nucleotidases.";
RL   Arch. Biochem. Biophys. 406:105-115(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Lung fibroblast;
RX   PubMed=12761501; DOI=10.1038/sj.onc.1206406;
RA   Matsuda A., Suzuki Y., Honda G., Muramatsu S., Matsuzaki O., Nagano Y.,
RA   Doi T., Shimotohno K., Harada T., Nishida E., Hayashi H., Sugano S.;
RT   "Large-scale identification and characterization of human genes that
RT   activate NF-kappaB and MAPK signaling pathways.";
RL   Oncogene 22:3307-3318(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Mammary gland, and Substantia nigra;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Ovary, Pancreas, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 141-401 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=12167635; DOI=10.1074/jbc.m201656200;
RA   Failer B.U., Braun N., Zimmermann H.;
RT   "Cloning, expression, and functional characterization of a Ca2+-dependent
RT   endoplasmic reticulum nucleoside diphosphatase.";
RL   J. Biol. Chem. 277:36978-36986(2002).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, AND MUTAGENESIS OF ASP-114;
RP   GLY-152; GLU-160; ARG-163; ASP-181; ASP-205 AND ARG-301.
RX   PubMed=15248776; DOI=10.1021/bi049565o;
RA   Yang M., Kirley T.L.;
RT   "Site-directed mutagenesis of human soluble calcium-activated nucleotidase
RT   1 (hSCAN-1): identification of residues essential for enzyme activity and
RT   the Ca(2+)-induced conformational change.";
RL   Biochemistry 43:9185-9194(2004).
RN   [7]
RP   INVOLVEMENT IN DBQD1.
RX   PubMed=20425819; DOI=10.1002/ajmg.a.33404;
RA   Faden M., Al-Zahrani F., Arafah D., Alkuraya F.S.;
RT   "Mutation of CANT1 causes Desbuquois dysplasia.";
RL   Am. J. Med. Genet. A 152:1157-1160(2010).
RN   [8]
RP   FUNCTION IN PROTEOGLYCAN SYNTHESIS, AND VARIANTS DBQD1 HIS-300; ARG-303 AND
RP   ASN-374.
RX   PubMed=22539336; DOI=10.1002/humu.22104;
RA   Nizon M., Huber C., De Leonardis F., Merrina R., Forlino A., Fradin M.,
RA   Tuysuz B., Abu-Libdeh B.Y., Alanay Y., Albrecht B., Al-Gazali L.,
RA   Basaran S.Y., Clayton-Smith J., Desir J., Gill H., Greally M.T.,
RA   Koparir E., van Maarle M.C., Mackay S., Mortier G., Morton J., Sillence D.,
RA   Vilain C., Young I., Zerres K., Le Merrer M., Munnich A., Le Goff C.,
RA   Rossi A., Cormier-Daire V.;
RT   "Further delineation of CANT1 phenotypic spectrum and demonstration of its
RT   role in proteoglycan synthesis.";
RL   Hum. Mutat. 33:1261-1266(2012).
RN   [9]
RP   INVOLVEMENT IN EDM7, AND VARIANTS EDM7 PHE-171 AND MET-226.
RX   PubMed=28742282; DOI=10.1002/ajmg.a.38349;
RA   Balasubramanian K., Li B., Krakow D., Nevarez L., Ho P.J., Ainsworth J.A.,
RA   Nickerson D.A., Bamshad M.J., Immken L., Lachman R.S., Cohn D.H.;
RT   "MED resulting from recessively inherited mutations in the gene encoding
RT   calcium-activated nucleotidase CANT1.";
RL   Am. J. Med. Genet. A 173:2415-2421(2017).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 71-401 IN COMPLEX WITH SUBSTRATE
RP   ANALOG AND CALCIUM IONS, CATALYTIC ACTIVITY, COFACTOR, SUBUNIT, AND
RP   MUTAGENESIS OF ASP-112; ASP-114; GLU-166; SER-168; ASP-169; ASP-182;
RP   GLU-215; GLU-246 AND ARG-301.
RX   PubMed=15006348; DOI=10.1016/s0092-8674(04)00172-2;
RA   Dai J., Liu J., Deng Y., Smith T.M., Lu M.;
RT   "Structure and protein design of a human platelet function inhibitor.";
RL   Cell 116:649-659(2004).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 69-401 IN COMPLEX WITH CALCIUM,
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, DIMERIZATION, SUBCELLULAR LOCATION,
RP   DISULFIDE BOND, AND MUTAGENESIS OF CYS-60; SER-139; GLU-160; ILE-200;
RP   SER-202; SER-256; CYS-287; SER-308 AND ALA-317.
RX   PubMed=16835225; DOI=10.1074/jbc.m604413200;
RA   Yang M., Horii K., Herr A.B., Kirley T.L.;
RT   "Calcium-dependent dimerization of human soluble calcium activated
RT   nucleotidase: characterization of the dimer interface.";
RL   J. Biol. Chem. 281:28307-28317(2006).
RN   [12]
RP   VARIANTS DBQD1 LEU-299; CYS-300 AND HIS-300.
RX   PubMed=19853239; DOI=10.1016/j.ajhg.2009.10.001;
RA   Huber C., Oules B., Bertoli M., Chami M., Fradin M., Alanay Y.,
RA   Al-Gazali L.I., Ausems M.G., Bitoun P., Cavalcanti D.P., Krebs A.,
RA   Le Merrer M., Mortier G., Shafeghati Y., Superti-Furga A., Robertson S.P.,
RA   Le Goff C., Muda A.O., Paterlini-Brechot P., Munnich A., Cormier-Daire V.;
RT   "Identification of CANT1 mutations in Desbuquois dysplasia.";
RL   Am. J. Hum. Genet. 85:706-710(2009).
RN   [13]
RP   VARIANT DBQD1 GLU-112.
RX   PubMed=21654728; DOI=10.1038/ejhg.2011.101;
RA   Laccone F., Schoner K., Krabichler B., Kluge B., Schwerdtfeger R.,
RA   Schulze B., Zschocke J., Rehder H.;
RT   "Desbuquois dysplasia type I and fetal hydrops due to novel mutations in
RT   the CANT1 gene.";
RL   Eur. J. Hum. Genet. 19:1133-1137(2011).
RN   [14]
RP   VARIANT DBQD1 MET-226.
RX   PubMed=21412251; DOI=10.1038/jhg.2011.28;
RA   Dai J., Kim O.H., Cho T.J., Miyake N., Song H.R., Karasugi T., Sakazume S.,
RA   Ikema M., Matsui Y., Nagai T., Matsumoto N., Ohashi H., Kamatani N.,
RA   Nishimura G., Furuichi T., Takahashi A., Ikegawa S.;
RT   "A founder mutation of CANT1 common in Korean and Japanese Desbuquois
RT   dysplasia.";
RL   J. Hum. Genet. 56:398-400(2011).
RN   [15]
RP   VARIANTS DBQD1 CYS-125; THR-165; PRO-224; MET-226 AND ASP-360,
RP   CHARACTERIZATION OF VARIANTS DBQD1 CYS-125; THR-165; PRO-224; MET-226;
RP   CYS-300 AND ASP-360, AND CHARACTERIZATION OF VARIANTS THR-323 AND GLU-391.
RX   PubMed=21037275; DOI=10.1136/jmg.2010.080226;
RA   Furuichi T., Dai J., Cho T.J., Sakazume S., Ikema M., Matsui Y., Baynam G.,
RA   Nagai T., Miyake N., Matsumoto N., Ohashi H., Unger S., Superti-Furga A.,
RA   Kim O.H., Nishimura G., Ikegawa S.;
RT   "CANT1 mutation is also responsible for Desbuquois dysplasia, type 2 and
RT   Kim variant.";
RL   J. Med. Genet. 48:32-37(2011).
CC   -!- FUNCTION: Calcium-dependent nucleotidase with a preference for UDP. The
CC       order of activity with different substrates is UDP > GDP > UTP > GTP.
CC       Has very low activity towards ADP and even lower activity towards ATP.
CC       Does not hydrolyze AMP and GMP (PubMed:12234496, PubMed:15248776,
CC       PubMed:15006348, PubMed:16835225). Involved in proteoglycan synthesis
CC       (PubMed:22539336). {ECO:0000269|PubMed:12234496,
CC       ECO:0000269|PubMed:15006348, ECO:0000269|PubMed:15248776,
CC       ECO:0000269|PubMed:16835225, ECO:0000269|PubMed:22539336}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a ribonucleoside 5'-diphosphate + H2O = a ribonucleoside 5'-
CC         phosphate + H(+) + phosphate; Xref=Rhea:RHEA:36799,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:57930, ChEBI:CHEBI:58043; EC=3.6.1.6;
CC         Evidence={ECO:0000269|PubMed:12234496, ECO:0000269|PubMed:15248776,
CC         ECO:0000269|PubMed:16835225};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:12234496, ECO:0000269|PubMed:15006348,
CC         ECO:0000269|PubMed:15248776, ECO:0000269|PubMed:16835225};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 6.8.;
CC   -!- SUBUNIT: Monomer (PubMed:12234496, PubMed:15006348). Homodimer;
CC       dimerization is Ca(2+)-dependent (PubMed:16835225). Homodimer;
CC       disulfide-linked (membrane form) (PubMed:16835225).
CC       {ECO:0000269|PubMed:12234496, ECO:0000269|PubMed:15006348,
CC       ECO:0000269|PubMed:16835225}.
CC   -!- INTERACTION:
CC       Q8WVQ1; P58418: CLRN1; NbExp=3; IntAct=EBI-16770554, EBI-17274839;
CC       Q8WVQ1; Q5JX71: FAM209A; NbExp=3; IntAct=EBI-16770554, EBI-18304435;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:12234496}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:12234496}. Golgi apparatus, Golgi stack membrane
CC       {ECO:0000269|PubMed:12234496}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:12234496}. Cell membrane
CC       {ECO:0000269|PubMed:16835225}. Note=Processed form: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8WVQ1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8WVQ1-2; Sequence=VSP_013760, VSP_013761;
CC       Name=3;
CC         IsoId=Q8WVQ1-3; Sequence=VSP_054260;
CC   -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:12234496}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:12234496}.
CC   -!- DISEASE: Desbuquois dysplasia 1 (DBQD1) [MIM:251450]: A
CC       chondrodysplasia characterized by severe prenatal and postnatal growth
CC       retardation (less than -5 SD), joint laxity, short extremities,
CC       progressive scoliosis, round face, midface hypoplasia, prominent
CC       bulging eyes. The main radiologic features are short long bones with
CC       metaphyseal splay, a 'Swedish key' appearance of the proximal femur
CC       (exaggerated trochanter), and advance carpal and tarsal bone age. Two
CC       forms of Desbuquois dysplasia are distinguished on the basis of the
CC       presence or absence of characteristic hand anomalies: an extra
CC       ossification center distal to the second metacarpal, delta phalanx,
CC       bifid distal thumb phalanx, and phalangeal dislocations.
CC       {ECO:0000269|PubMed:19853239, ECO:0000269|PubMed:20425819,
CC       ECO:0000269|PubMed:21037275, ECO:0000269|PubMed:21412251,
CC       ECO:0000269|PubMed:21654728, ECO:0000269|PubMed:22539336}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Epiphyseal dysplasia, multiple, 7 (EDM7) [MIM:617719]: A form
CC       of multiple epiphyseal dysplasia, a generalized skeletal dysplasia
CC       associated with significant morbidity. Joint pain, joint deformity,
CC       waddling gait, and short stature are the main clinical signs and
CC       symptoms. Radiological examination of the skeleton shows delayed,
CC       irregular mineralization of the epiphyseal ossification centers and of
CC       the centers of the carpal and tarsal bones. Multiple epiphyseal
CC       dysplasia is broadly categorized into the more severe Fairbank and the
CC       milder Ribbing types. The Fairbank type is characterized by shortness
CC       of stature, short and stubby fingers, small epiphyses in several
CC       joints, including the knee, ankle, hand, and hip. The Ribbing type is
CC       confined predominantly to the hip joints and is characterized by hands
CC       that are normal and stature that is normal or near-normal. EDM7
CC       inheritance is autosomal recessive. {ECO:0000269|PubMed:28742282}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- MISCELLANEOUS: Not inhibited by azide.
CC   -!- SIMILARITY: Belongs to the apyrase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAM94564.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF328554; AAM94564.1; ALT_INIT; mRNA.
DR   EMBL; AB097006; BAC77359.1; -; mRNA.
DR   EMBL; AB097033; BAC77386.1; -; mRNA.
DR   EMBL; AK074687; BAC11139.1; -; mRNA.
DR   EMBL; AK295930; BAG58716.1; -; mRNA.
DR   EMBL; BC005104; AAH05104.1; -; mRNA.
DR   EMBL; BC017655; AAH17655.1; -; mRNA.
DR   EMBL; BC065038; AAH65038.1; -; mRNA.
DR   EMBL; AJ312208; CAC85468.1; -; mRNA.
DR   CCDS; CCDS11760.1; -. [Q8WVQ1-1]
DR   RefSeq; NP_001153244.1; NM_001159772.1. [Q8WVQ1-1]
DR   RefSeq; NP_001153245.1; NM_001159773.1. [Q8WVQ1-1]
DR   RefSeq; NP_620148.1; NM_138793.3. [Q8WVQ1-1]
DR   RefSeq; XP_005257078.1; XM_005257021.1.
DR   RefSeq; XP_005257079.1; XM_005257022.1.
DR   RefSeq; XP_006721746.1; XM_006721683.1.
DR   RefSeq; XP_011522593.1; XM_011524291.1.
DR   RefSeq; XP_011522595.1; XM_011524293.1.
DR   RefSeq; XP_011522596.1; XM_011524294.1.
DR   RefSeq; XP_011522597.1; XM_011524295.2.
DR   PDB; 1S18; X-ray; 1.70 A; A/B=71-401.
DR   PDB; 1S1D; X-ray; 1.60 A; A/B=71-401.
DR   PDB; 2H2N; X-ray; 2.30 A; A/B=69-401.
DR   PDB; 2H2U; X-ray; 2.40 A; A/B=69-401.
DR   PDBsum; 1S18; -.
DR   PDBsum; 1S1D; -.
DR   PDBsum; 2H2N; -.
DR   PDBsum; 2H2U; -.
DR   AlphaFoldDB; Q8WVQ1; -.
DR   SMR; Q8WVQ1; -.
DR   BioGRID; 125875; 88.
DR   IntAct; Q8WVQ1; 16.
DR   MINT; Q8WVQ1; -.
DR   STRING; 9606.ENSP00000307674; -.
DR   DrugBank; DB03486; Phosphomethylphosphonic acid guanosyl ester.
DR   GlyConnect; 1760; 4 N-Linked glycans (1 site).
DR   GlyCosmos; Q8WVQ1; 1 site, 4 glycans.
DR   GlyGen; Q8WVQ1; 2 sites, 4 N-linked glycans (1 site).
DR   iPTMnet; Q8WVQ1; -.
DR   PhosphoSitePlus; Q8WVQ1; -.
DR   SwissPalm; Q8WVQ1; -.
DR   BioMuta; CANT1; -.
DR   DMDM; 66774052; -.
DR   EPD; Q8WVQ1; -.
DR   jPOST; Q8WVQ1; -.
DR   MassIVE; Q8WVQ1; -.
DR   MaxQB; Q8WVQ1; -.
DR   PaxDb; Q8WVQ1; -.
DR   PeptideAtlas; Q8WVQ1; -.
DR   ProteomicsDB; 74813; -. [Q8WVQ1-1]
DR   ProteomicsDB; 74814; -. [Q8WVQ1-2]
DR   Antibodypedia; 19748; 351 antibodies from 31 providers.
DR   DNASU; 124583; -.
DR   Ensembl; ENST00000302345.6; ENSP00000307674.2; ENSG00000171302.17. [Q8WVQ1-1]
DR   Ensembl; ENST00000392446.10; ENSP00000376241.4; ENSG00000171302.17. [Q8WVQ1-1]
DR   Ensembl; ENST00000591773.5; ENSP00000467437.1; ENSG00000171302.17. [Q8WVQ1-1]
DR   Ensembl; ENST00000620915.4; ENSP00000477798.1; ENSG00000171302.17. [Q8WVQ1-1]
DR   GeneID; 124583; -.
DR   KEGG; hsa:124583; -.
DR   MANE-Select; ENST00000392446.10; ENSP00000376241.4; NM_001159773.2; NP_001153245.1.
DR   UCSC; uc002jwj.4; human. [Q8WVQ1-1]
DR   AGR; HGNC:19721; -.
DR   CTD; 124583; -.
DR   DisGeNET; 124583; -.
DR   GeneCards; CANT1; -.
DR   HGNC; HGNC:19721; CANT1.
DR   HPA; ENSG00000171302; Low tissue specificity.
DR   MalaCards; CANT1; -.
DR   MIM; 251450; phenotype.
DR   MIM; 613165; gene.
DR   MIM; 617719; phenotype.
DR   neXtProt; NX_Q8WVQ1; -.
DR   OpenTargets; ENSG00000171302; -.
DR   Orphanet; 1425; Desbuquois syndrome.
DR   PharmGKB; PA134984439; -.
DR   VEuPathDB; HostDB:ENSG00000171302; -.
DR   eggNOG; KOG4494; Eukaryota.
DR   GeneTree; ENSGT00390000012872; -.
DR   HOGENOM; CLU_047493_0_0_1; -.
DR   InParanoid; Q8WVQ1; -.
DR   OMA; HENWVSH; -.
DR   OrthoDB; 1242at2759; -.
DR   PhylomeDB; Q8WVQ1; -.
DR   TreeFam; TF315248; -.
DR   BRENDA; 3.6.1.5; 2681.
DR   PathwayCommons; Q8WVQ1; -.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SignaLink; Q8WVQ1; -.
DR   BioGRID-ORCS; 124583; 23 hits in 1155 CRISPR screens.
DR   ChiTaRS; CANT1; human.
DR   EvolutionaryTrace; Q8WVQ1; -.
DR   GeneWiki; CANT1; -.
DR   GenomeRNAi; 124583; -.
DR   Pharos; Q8WVQ1; Tbio.
DR   PRO; PR:Q8WVQ1; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q8WVQ1; protein.
DR   Bgee; ENSG00000171302; Expressed in pancreatic ductal cell and 190 other tissues.
DR   ExpressionAtlas; Q8WVQ1; baseline and differential.
DR   Genevisible; Q8WVQ1; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0032580; C:Golgi cisterna membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0035580; C:specific granule lumen; TAS:Reactome.
DR   GO; GO:1904724; C:tertiary granule lumen; TAS:Reactome.
DR   GO; GO:0043262; F:ADP phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0004382; F:GDP phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0045134; F:UDP phosphatase activity; IBA:GO_Central.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; HMP:UniProtKB.
DR   GO; GO:0030166; P:proteoglycan biosynthetic process; IMP:UniProtKB.
DR   Gene3D; 2.120.10.100; Apyrase; 1.
DR   InterPro; IPR009283; Apyrase.
DR   InterPro; IPR036258; Apyrase_sf.
DR   PANTHER; PTHR13023; APYRASE; 1.
DR   PANTHER; PTHR13023:SF3; SOLUBLE CALCIUM-ACTIVATED NUCLEOTIDASE 1; 1.
DR   Pfam; PF06079; Apyrase; 1.
DR   SUPFAM; SSF101887; Apyrase; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell membrane;
KW   Disease variant; Disulfide bond; Dwarfism; Endoplasmic reticulum;
KW   Glycoprotein; Golgi apparatus; Hydrolase; Membrane; Metal-binding;
KW   Reference proteome; Signal-anchor; Transmembrane; Transmembrane helix.
FT   CHAIN           1..401
FT                   /note="Soluble calcium-activated nucleotidase 1"
FT                   /id="PRO_0000209925"
FT   TOPO_DOM        1..44
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        45..62
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        63..401
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   BINDING         168
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:15006348,
FT                   ECO:0000269|PubMed:16835225, ECO:0007744|PDB:1S18,
FT                   ECO:0007744|PDB:1S1D, ECO:0007744|PDB:2H2N,
FT                   ECO:0007744|PDB:2H2U"
FT   BINDING         169
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:15006348,
FT                   ECO:0000269|PubMed:16835225, ECO:0007744|PDB:1S18,
FT                   ECO:0007744|PDB:2H2N, ECO:0007744|PDB:2H2U"
FT   BINDING         215
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:15006348,
FT                   ECO:0000269|PubMed:16835225, ECO:0007744|PDB:1S18,
FT                   ECO:0007744|PDB:1S1D, ECO:0007744|PDB:2H2N,
FT                   ECO:0007744|PDB:2H2U"
FT   BINDING         284
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:15006348,
FT                   ECO:0000269|PubMed:16835225, ECO:0007744|PDB:1S18,
FT                   ECO:0007744|PDB:1S1D, ECO:0007744|PDB:2H2N,
FT                   ECO:0007744|PDB:2H2U"
FT   BINDING         345
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:15006348,
FT                   ECO:0000269|PubMed:16835225, ECO:0007744|PDB:1S18,
FT                   ECO:0007744|PDB:1S1D, ECO:0007744|PDB:2H2N,
FT                   ECO:0007744|PDB:2H2U"
FT   BINDING         396
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:15006348,
FT                   ECO:0000269|PubMed:16835225, ECO:0007744|PDB:1S18,
FT                   ECO:0007744|PDB:1S1D, ECO:0007744|PDB:2H2N,
FT                   ECO:0007744|PDB:2H2U"
FT   SITE            160
FT                   /note="Important for dimer formation"
FT                   /evidence="ECO:0000269|PubMed:16835225"
FT   SITE            200
FT                   /note="Important for dimer formation"
FT                   /evidence="ECO:0000269|PubMed:16835225"
FT   SITE            202
FT                   /note="Important for dimer formation"
FT                   /evidence="ECO:0000269|PubMed:16835225"
FT   SITE            256
FT                   /note="Important for dimer formation"
FT                   /evidence="ECO:0000269|PubMed:16835225"
FT   CARBOHYD        88
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        60
FT                   /note="Interchain"
FT                   /evidence="ECO:0000269|PubMed:16835225"
FT   VAR_SEQ         41..91
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054260"
FT   VAR_SEQ         220..245
FT                   /note="KDERLYVGGLGKEWTTTTGDVVNENP -> REIVRKRWRLVKQVSHVGVLGQ
FT                   WIQR (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:12761501"
FT                   /id="VSP_013760"
FT   VAR_SEQ         246..401
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:12761501"
FT                   /id="VSP_013761"
FT   VARIANT         112
FT                   /note="D -> E (in DBQD1; dbSNP:rs749246739)"
FT                   /evidence="ECO:0000269|PubMed:21654728"
FT                   /id="VAR_068655"
FT   VARIANT         125
FT                   /note="W -> C (in DBQD1; severely affects activity;
FT                   dbSNP:rs587776898)"
FT                   /evidence="ECO:0000269|PubMed:21037275"
FT                   /id="VAR_068656"
FT   VARIANT         165
FT                   /note="M -> T (in DBQD1; severely affects activity)"
FT                   /evidence="ECO:0000269|PubMed:21037275"
FT                   /id="VAR_068657"
FT   VARIANT         171
FT                   /note="I -> F (in EDM7; unknown pathological significance;
FT                   dbSNP:rs1014317450)"
FT                   /evidence="ECO:0000269|PubMed:28742282"
FT                   /id="VAR_080400"
FT   VARIANT         224
FT                   /note="L -> P (in DBQD1; affects protein stability and
FT                   secretion; dbSNP:rs150181226)"
FT                   /evidence="ECO:0000269|PubMed:21037275"
FT                   /id="VAR_068658"
FT   VARIANT         226
FT                   /note="V -> M (in DBQD1 and EDM7; severely affects
FT                   activity; dbSNP:rs377546036)"
FT                   /evidence="ECO:0000269|PubMed:21037275,
FT                   ECO:0000269|PubMed:21412251, ECO:0000269|PubMed:28742282"
FT                   /id="VAR_068659"
FT   VARIANT         299
FT                   /note="P -> L (in DBQD1; dbSNP:rs267606700)"
FT                   /evidence="ECO:0000269|PubMed:19853239"
FT                   /id="VAR_062980"
FT   VARIANT         300
FT                   /note="R -> C (in DBQD1; severely affects activity;
FT                   dbSNP:rs267606701)"
FT                   /evidence="ECO:0000269|PubMed:19853239,
FT                   ECO:0000269|PubMed:21037275"
FT                   /id="VAR_062981"
FT   VARIANT         300
FT                   /note="R -> H (in DBQD1; dbSNP:rs267606699)"
FT                   /evidence="ECO:0000269|PubMed:19853239,
FT                   ECO:0000269|PubMed:22539336"
FT                   /id="VAR_062982"
FT   VARIANT         303
FT                   /note="S -> R (in DBQD1)"
FT                   /evidence="ECO:0000269|PubMed:22539336"
FT                   /id="VAR_068660"
FT   VARIANT         323
FT                   /note="A -> T (does not affect activity; dbSNP:rs9903215)"
FT                   /evidence="ECO:0000269|PubMed:21037275"
FT                   /id="VAR_068661"
FT   VARIANT         360
FT                   /note="A -> D (in DBQD1; affects protein secretion;
FT                   dbSNP:rs387907081)"
FT                   /evidence="ECO:0000269|PubMed:21037275"
FT                   /id="VAR_068662"
FT   VARIANT         374
FT                   /note="I -> N (in DBQD1)"
FT                   /evidence="ECO:0000269|PubMed:22539336"
FT                   /id="VAR_068663"
FT   VARIANT         391
FT                   /note="G -> E (does not affect activity; dbSNP:rs34082669)"
FT                   /evidence="ECO:0000269|PubMed:21037275"
FT                   /id="VAR_068664"
FT   MUTAGEN         60
FT                   /note="C->S: Loss of dimer formation."
FT                   /evidence="ECO:0000269|PubMed:16835225"
FT   MUTAGEN         112
FT                   /note="D->A: Reduces activity by 99%."
FT                   /evidence="ECO:0000269|PubMed:15006348"
FT   MUTAGEN         114
FT                   /note="D->A: Reduces activity by 99%."
FT                   /evidence="ECO:0000269|PubMed:15006348,
FT                   ECO:0000269|PubMed:15248776"
FT   MUTAGEN         139
FT                   /note="S->C: Reduces GDPase and ADPase activities 1.7-fold.
FT                   Severe loss of dimer formation; when associated with
FT                   S-287."
FT                   /evidence="ECO:0000269|PubMed:16835225"
FT   MUTAGEN         152
FT                   /note="G->E: Slightly reduced activity."
FT                   /evidence="ECO:0000269|PubMed:15248776"
FT   MUTAGEN         160
FT                   /note="E->Y: Increases GDPase activity 2-fold and ADPase
FT                   activity 5-fold. Forms dimer even at suboptimal Ca(2+)
FT                   concentrations."
FT                   /evidence="ECO:0000269|PubMed:15248776,
FT                   ECO:0000269|PubMed:16835225"
FT   MUTAGEN         163
FT                   /note="R->A: Reduces activity by 98%."
FT                   /evidence="ECO:0000269|PubMed:15248776"
FT   MUTAGEN         166
FT                   /note="E->Q: Reduces activity by 95%."
FT                   /evidence="ECO:0000269|PubMed:15006348"
FT   MUTAGEN         168
FT                   /note="S->A: Reduces activity by over 99.9%."
FT                   /evidence="ECO:0000269|PubMed:15006348"
FT   MUTAGEN         169
FT                   /note="D->N: Reduces activity by 96%."
FT                   /evidence="ECO:0000269|PubMed:15006348"
FT   MUTAGEN         181
FT                   /note="D->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:15248776"
FT   MUTAGEN         182
FT                   /note="D->N: Reduces activity by over 99.9%."
FT                   /evidence="ECO:0000269|PubMed:15006348"
FT   MUTAGEN         200
FT                   /note="I->C: Reduces GDPase activity 2-fold and ADPase
FT                   activity 2.5-fold. No effect on dimer formation; when
FT                   associated with S-287."
FT                   /evidence="ECO:0000269|PubMed:16835225"
FT   MUTAGEN         202
FT                   /note="S->C: Reduces GDPase activity 1.7-fold and ADPase
FT                   activity 1.5-fold. No effect on dimer formation; when
FT                   associated with S-287."
FT                   /evidence="ECO:0000269|PubMed:16835225"
FT   MUTAGEN         205
FT                   /note="D->A: Slightly reduced activity."
FT                   /evidence="ECO:0000269|PubMed:15248776"
FT   MUTAGEN         215
FT                   /note="E->Q: Reduces activity by 99%."
FT                   /evidence="ECO:0000269|PubMed:15006348"
FT   MUTAGEN         246
FT                   /note="E->M: Increases activity 5-fold."
FT                   /evidence="ECO:0000269|PubMed:15006348"
FT   MUTAGEN         256
FT                   /note="S->C: No effect on GDPase and ADPase activities. No
FT                   effect on dimer formation; when associated with S-287."
FT                   /evidence="ECO:0000269|PubMed:16835225"
FT   MUTAGEN         287
FT                   /note="C->S: Reduces GDPase and ADPase activities
FT                   1.3-fold."
FT                   /evidence="ECO:0000269|PubMed:16835225"
FT   MUTAGEN         301
FT                   /note="R->A: Reduces activity by 99%."
FT                   /evidence="ECO:0000269|PubMed:15006348,
FT                   ECO:0000269|PubMed:15248776"
FT   MUTAGEN         308
FT                   /note="S->C: Reduces GDPase activity 1.3-fold and ADPase
FT                   activity 2-fold. Severe loss of dimer formation; when
FT                   associated with S-287."
FT                   /evidence="ECO:0000269|PubMed:16835225"
FT   MUTAGEN         317
FT                   /note="A->C: Reduces GDPase activity 1.7-fold and ADPase
FT                   activity 1.5-fold. Severe loss of dimer formation; when
FT                   associated with S-287."
FT                   /evidence="ECO:0000269|PubMed:16835225"
FT   STRAND          92..94
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          97..99
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          102..112
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   HELIX           114..117
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          125..137
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          143..147
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          152..157
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          158..160
FT                   /evidence="ECO:0007829|PDB:2H2U"
FT   STRAND          167..173
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          176..181
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   TURN            182..184
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          186..191
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          194..200
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   TURN            204..207
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          208..211
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          216..220
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          223..227
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          240..242
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   HELIX           244..246
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          247..251
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          257..261
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   HELIX           263..272
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          280..282
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          286..289
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   TURN            290..293
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          294..297
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          300..305
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   HELIX           309..312
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          319..323
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          330..334
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          342..349
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          357..366
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          369..378
FT                   /evidence="ECO:0007829|PDB:1S1D"
FT   STRAND          383..400
FT                   /evidence="ECO:0007829|PDB:1S1D"
SQ   SEQUENCE   401 AA;  44840 MW;  5B78EB24C0B2C4CA CRC64;
     MPVQLSEHPE WNESMHSLRI SVGGLPVLAS MTKAADPRFR PRWKVILTFF VGAAILWLLC
     SHRPAPGRPP THNAHNWRLG QAPANWYNDT YPLSPPQRTP AGIRYRIAVI ADLDTESRAQ
     EENTWFSYLK KGYLTLSDSG DKVAVEWDKD HGVLESHLAE KGRGMELSDL IVFNGKLYSV
     DDRTGVVYQI EGSKAVPWVI LSDGDGTVEK GFKAEWLAVK DERLYVGGLG KEWTTTTGDV
     VNENPEWVKV VGYKGSVDHE NWVSNYNALR AAAGIQPPGY LIHESACWSD TLQRWFFLPR
     RASQERYSEK DDERKGANLL LSASPDFGDI AVSHVGAVVP THGFSSFKFI PNTDDQIIVA
     LKSEEDSGRV ASYIMAFTLD GRFLLPETKI GSVKYEGIEF I
//
